Dr. Reddy'S Laboratories
RDY
Dr. Reddy'S Laboratories (RDY) earnings history
Most recent quarter
- Fiscal period
- Q1 2027
- Period end
- Jun 30, 2026
- EPS actual
- $0.06
- EPS estimate
- $0.09
- EPS surprise
- −39.87%
- Revenue surprise
- −1.75%
- Revenue
- $835.7M
- Revenue estimate
- $850.6M
- Reported
- Jul 22, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2027 | Jul 22, 2026 | $0.09 | $0.06 | −39.87% | $835.7M | SEC |
| Q4 2026 | May 12, 2026 | $0.11 | $0.07 | −31.15% | $787.5M | SEC |
| Q3 2026 | Jan 21, 2026 | $0.16 | $0.16 | −2.40% | $951.6M | SEC |
| Q2 2026 | Oct 24, 2025 | $0.19 | $0.20 | +1.92% | $1.0B | SEC |
| Q1 2026 | Jul 23, 2025 | $0.21 | $0.20 | −8.12% | $988.9M | SEC |
| Q4 2025 | May 9, 2025 | $0.21 | $0.22 | +5.82% | $996.2M | SEC |
| Q3 2025 | Jan 23, 2025 | $0.21 | $0.20 | −5.98% | $969.6M | SEC |
| Q2 2025 | Nov 5, 2024 | $0.21 | $0.18 | −13.57% | $951.1M | SEC |
| Q1 2025 | Jul 29, 2024 | $0.19 | $0.20 | +3.64% | $916.3M | SEC |
| Q4 2024 | May 7, 2024 | $0.18 | $0.19 | +6.35% | $848.1M | SEC |
| Q3 2024 | Jan 30, 2024 | $0.18 | $0.20 | +12.68% | $868.0M | SEC |
| Q2 2024 | Oct 27, 2023 | $0.17 | $0.21 | +22.16% | $826.4M | SEC |
| Q1 2024 | Jul 26, 2023 | $0.15 | $0.21 | +33.51% | $822.4M | SEC |
| Q4 2023 | May 10, 2023 | $0.12 | $0.14 | +21.98% | $767.0M | SEC |
| Q3 2023 | Jan 25, 2023 | $0.14 | $0.18 | +35.07% | $829.8M | SEC |
| Q2 2023 | Oct 28, 2022 | $0.11 | $0.16 | +43.67% | $764.6M | — |
| Q1 2023 | Jul 28, 2022 | $0.10 | $0.18 | +75.15% | $653.9M | — |
| Q4 2022 | May 19, 2022 | $0.10 | $0.13 | +27.38% | $699.4M | — |
| Q3 2022 | Jan 28, 2022 | $0.13 | $0.11 | −11.15% | $708.9M | — |
| Q2 2022 | Oct 29, 2021 | $0.11 | $0.16 | +41.73% | $769.7M | — |
Quarterly revenue
Frequently asked questions
When did Dr. Reddy'S Laboratories (RDY) last report earnings?
Dr. Reddy'S Laboratories last reported on Jul 22, 2026, covering fiscal Q1 2027.
Did RDY beat earnings estimates?
No. Dr. Reddy'S Laboratories reported EPS of $0.06 for Q1 2027 against a $0.09 estimate — a 39.87% miss.
How much revenue did RDY report last quarter?
Dr. Reddy'S Laboratories reported $835.7M in revenue for Q1 2027, against a consensus estimate of $850.6M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.